Skip to main content

Table 1 Baseline characteristics by cigarette smoking

From: Compartmentalization of anti-oxidant and anti-inflammatory gene expression in current and former smokers with COPD

 

Total

Former Smoker

Current Smoker

P-value

N

89

35

54

 

Years of age, median (IQR)

58 (54–65)

65 (59–69)

55 (51–60)

<.001

Male, n (%)

54 (61%)

25 (71%)

29 (54%)

0.12

Race or ethnic group, n (%)

 White

51 (57%)

24 (69%)

27 (50%)

0.12

 Black

38 (43%)

11 (31%)

26 (48%)

0.12

 Hispanic

1 (1%)

0 (0%)

1 (2%)

 

Smoking history median (IQR)

 Current cigarettes/day

  

10 (5–20)

 

 Age started smoking

15 (13–18)

15 (13–18)

15 (13–17)

0.34

 Years since quitting

10 (4–15)

10 (4–15)

  

 Pack years (packs * years smoking)

39 (25–56)

39 (27–62)

39 (23–53)

0.66

COPD Characteristics n (%)

 COPD exacerbation, prior 12 months

19 (21%)

4 (11%)

15 (28%)

0.11

 FEV1 (%predicted)

61 (53–70)

57 (53–65)

64 (53–71)

0.18

 FEV1/FVC ratio

0.56 (0.48–0.62)

0.53 (0.46–0.59)

0.57 (0.50–0.63)

0.09

 DLCO (mL/mm/mmHg)

15.7 (12.1–20.9)

16.1 (11.9–21.2)

15.7 (12.1–20.9)

0.95

 TLC (Liters)

6.0 (5.0–7.2)

6.3 (5.3–7.4)

5.7 (5.0–7.0)

0.2

 SVC (Liters)

3.3 (2.7–4.1)

3.7 (2.7–4.2)

3.2 (2.6–4.0)

0.49

 FRC (Liters)

3.5 (3.0–4.2)

3.6 (3.0–4.1)

3.5 (3.0–4.2)

0.76

 RV (Liters)

2.6 (2.2–3.2)

2.7 (2.4–3.5)

2.6 (1.9–3.0)

0.09

 Pulse oximetry (%)

96 (94–97)

95 (93–97)

96 (95–98)

0.01

 Short acting beta-agonist (SABA)

61 (69%)

22 (63%)

39 (72%)

0.36

 LABA and inhaled corticosteroid

40 (45%)

17 (49%)

23 (43%)

0.66

 Long-acting anticholinergic

26 (29%)

11 (31%)

15 (28%)

0.81

 Aspirin

22 (25%)

14 (40%)

8 (15%)

0.01

Questionnairre scores (median (IQR)

 Medical Research Council Dyspnea

2 (1–3)

2 (1–3)

2 (1–3)

0.41

 St George’s Respiratory

40 (26–56)

39 (26–56)

46 (26–62)

0.42

  1. Abbreviations: FEV1 Forced expired volume in 1 s, FVC Forced vital capacity, DLCO Diffusing capacity of the lungs for carbon monoxide, TLC Total lung capacity, SVC Slow vital capacity, FRC Functional residual volume, RV Residual volume